Royce & Associates LP Takes Position in OptimizeRx Co. (NASDAQ:OPRX)

Royce & Associates LP purchased a new position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,069,560 shares of the company's stock, valued at approximately $5,198,000. Royce & Associates LP owned about 5.81% of OptimizeRx as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of OPRX. SBI Securities Co. Ltd. bought a new position in shares of OptimizeRx in the 4th quarter worth about $25,000. BNP Paribas Financial Markets lifted its position in shares of OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock worth $28,000 after buying an additional 2,414 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of OptimizeRx in the 4th quarter worth about $51,000. Quest Partners LLC increased its holdings in shares of OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company's stock worth $76,000 after acquiring an additional 9,739 shares during the period. Finally, Barclays PLC increased its holdings in shares of OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock worth $208,000 after acquiring an additional 21,060 shares during the period. 76.47% of the stock is currently owned by institutional investors.

Insider Activity at OptimizeRx

In other OptimizeRx news, Director James Paul Lang acquired 321,408 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were purchased at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.10% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of analysts recently weighed in on OPRX shares. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $6.00 price objective (down previously from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. JMP Securities reissued a "market outperform" rating and set a $8.00 target price on shares of OptimizeRx in a research note on Thursday, February 6th. B. Riley upgraded shares of OptimizeRx to a "strong-buy" rating in a research report on Wednesday, March 12th. Stephens assumed coverage on shares of OptimizeRx in a report on Friday, December 20th. They issued an "equal weight" rating and a $5.50 target price for the company. Finally, Lake Street Capital reiterated a "buy" rating and issued a $11.00 target price on shares of OptimizeRx in a report on Tuesday, December 24th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, OptimizeRx presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.06.

OptimizeRx Stock Down 1.8 %

OPRX traded down $0.16 during midday trading on Friday, hitting $8.63. 340,091 shares of the company's stock traded hands, compared to its average volume of 257,374. The company has a market cap of $158.97 million, a PE ratio of -6.49 and a beta of 1.31. The stock's fifty day simple moving average is $5.84 and its 200-day simple moving average is $5.93. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. OptimizeRx Co. has a one year low of $3.78 and a one year high of $14.13.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.